M M. Véniant, et.al., Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100., The Journal of clinical investigation, 1997, 100

http://rdf.ncbi.nlm.nih.gov/pubmed/9202070

M M. Véniant, et.al., Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100., The Journal of clinical investigation, 1997, 100

pubmed

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• increased circulating triglyceride level_Apob<tm1Sgy>/Apob<tm1Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0001552I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm1SgyApobtm1SgyApoetm1UncApoetm1UncApoetm1UncApobtm1Sgy
• decreased susceptibility to atherosclerosis_Apob<tm2Sgy>/Apob<tm2Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005341I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm2SgyApobtm2SgyApoetm1UncApoetm1UncApoetm1UncApobtm2Sgy
• increased circulating VLDL cholesterol level_Apob<tm1Sgy>/Apob<tm1Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005145I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm1SgyApobtm1SgyApoetm1UncApoetm1UncApoetm1UncApobtm1Sgy
• increased body weight_Apob<tm1Sgy>/Apob<tm1Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0001260I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm1SgyApobtm1SgyApoetm1UncApoetm1UncApoetm1UncApobtm1Sgy
• abnormal cholesterol homeostasis_Apob<tm2Sgy>/Apob<tm2Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005278I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm2SgyApobtm2SgyApoetm1UncApoetm1UncApoetm1UncApobtm2Sgy
• increased circulating VLDL cholesterol level_Apob<tm2Sgy>/Apob<tm2Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005145I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm2SgyApobtm2SgyApoetm1UncApoetm1UncApoetm1UncApobtm2Sgy
• increased circulating VLDL cholesterol level_Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005145I129P2OlaHsdC57BL6Apoetm1UncApoetm1UncApoetm1Unc
• decreased circulating cholesterol level_Apob<tm2Sgy>/Apob<tm2Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005179I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm2SgyApobtm2SgyApoetm1UncApoetm1UncApoetm1UncApobtm2Sgy
• increased susceptibility to atherosclerosis_Apob<tm1Sgy>/Apob<tm1Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005339I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm1SgyApobtm1SgyApoetm1UncApoetm1UncApoetm1UncApobtm1Sgy
• increased circulating VLDL triglyceride level_Apob<tm2Sgy>/Apob<tm2Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0003975I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm2SgyApobtm2SgyApoetm1UncApoetm1UncApoetm1UncApobtm2Sgy
• increased circulating cholesterol level_Apob<tm1Sgy>/Apob<tm1Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005178I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm1SgyApobtm1SgyApoetm1UncApoetm1UncApoetm1UncApobtm1Sgy
• decreased body weight_Apob<tm2Sgy>/Apob<tm2Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0001262I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm2SgyApobtm2SgyApoetm1UncApoetm1UncApoetm1UncApobtm2Sgy
• atherosclerotic lesions_Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005338I129P2OlaHsdC57BL6Apoetm1UncApoetm1UncApoetm1Unc
• increased circulating HDL cholesterol level_Apob<tm2Sgy>/Apob<tm2Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0001556I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm2SgyApobtm2SgyApoetm1UncApoetm1UncApoetm1UncApobtm2Sgy
• increased circulating cholesterol level_Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0005178I129P2OlaHsdC57BL6Apoetm1UncApoetm1UncApoetm1Unc
• increased circulating triglyceride level_Apob<tm2Sgy>/Apob<tm2Sgy>,Apoe<tm1Unc>/Apoe<tm1Unc>
  http://metadb.riken.jp/0001552I129P2OlaHsd129S7SvEvBrdC57BL6Apobtm2SgyApobtm2SgyApoetm1UncApoetm1UncApoetm1UncApobtm2Sgy